(CercleFinance.com) – Eli Lilly announced today that it has completed the acquisition of DICE Therapeutics, allowing it to expand its immunology portfolio to include new oral therapeutic candidates from DICE, including oral inhibitors in clinical development to treat chronic diseases in immunology.
Eli Lilly’s takeover bid to acquire all of the issued and outstanding shares of DICE, at a purchase price of $48 per share expired as scheduled on August 8, 2023 and has not been extended further.
When the offer expired, 42,265,390 shares had been validly tendered, representing approximately 88.4% of the issued and outstanding shares.
Eli Lilly says DICE common stock will be delisted from the NASDAQ Global Market.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
